Log in
Enquire now
‌

US Patent 9790195 KDM1A inhibitors for the treatment of disease

Patent 9790195 was granted and assigned to Imago BioSciences Inc on October, 2017 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent
0

Patent attributes

Patent Applicant
Imago BioSciences Inc
Imago BioSciences Inc
0
Current Assignee
Imago BioSciences Inc
Imago BioSciences Inc
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
97901950
Patent Inventor Names
John M. McCall0
Hugh Young Rienhoff, Jr.0
Michael Clare0
Date of Patent
October 17, 2017
0
Patent Application Number
149104230
Date Filed
August 6, 2014
0
Patent Citations Received
‌
US Patent 11773068 KDM1A inhibitors for the treatment of disease
‌
US Patent 11932629 KDM1A inhibitors for the treatment of disease
0
‌
US Patent 11655226 KDM1A inhibitors for the treatment of disease
0
Patent Primary Examiner
‌
Erich A Leeser
0
Patent abstract

Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of KDMIA, methods of increasing gamma globin gene expression, and methods to induce differentiation of cancer cells in a human or animal subject are also provided for the treatment of diseases such as acute myelogenous leukemia.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 9790195 KDM1A inhibitors for the treatment of disease

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us